Cargando…

Evaluation of a locked nucleic acid form of antisense oligo targeting HIF-1α in advanced hepatocellular carcinoma

BACKGROUND: Hypoxia-inducible factor 1α (HIF-1α) is a gene that regulates tumor survival, neovascularization and invasion. Overexpression of HIF-1α correlates with poor prognosis in hepatocellular carcinoma (HCC). RO7070179 is a HIF-1α inhibitor that decreases HIF-1α mRNA and its downstream targets,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Jennifer, Contratto, Merly, Shanbhogue, Krishna P, Manji, Gulam A, O’Neil, Bert H, Noonan, Anne, Tudor, Robert, Lee, Ray
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2019
Materias:	Clinical Trials Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6441661/ https://www.ncbi.nlm.nih.gov/pubmed/30949444 http://dx.doi.org/10.5306/wjco.v10.i3.149

Ejemplares similares

Sequence motifs associated with hepatotoxicity of locked nucleic acid—modified antisense oligonucleotides
por: Burdick, Andrew D., et al.
Publicado: (2014)

Targeted therapy or immunotherapy? Optimal treatment in hepatocellular carcinoma
por: Contratto, Merly, et al.
Publicado: (2018)

Intracranial delivery of antisense locked nucleic acids for silencing microRNAs in the mouse brain
por: Sharma, Nikhil, et al.
Publicado: (2022)

Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals
por: Swayze, Eric E., et al.
Publicado: (2007)

Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents
por: Stein, C. A., et al.
Publicado: (2010)

Targeting murine alveolar macrophages by the intratracheal administration of locked nucleic acid containing antisense oligonucleotides
por: Uemura, Yasunori, et al.
Publicado: (2019)

Synthesis and biophysical properties of carbamate-locked nucleic acid (LNA) oligonucleotides with potential antisense applications
por: Thorpe, Cameron, et al.
Publicado: (2019)

Chemical Diversity of Locked Nucleic Acid-Modified Antisense Oligonucleotides Allows Optimization of Pharmaceutical Properties
por: Papargyri, Natalia, et al.
Publicado: (2019)

Identification and characterization of a MAPT-targeting locked nucleic acid antisense oligonucleotide therapeutic for tauopathies
por: Easton, Amy, et al.
Publicado: (2022)

Short antisense-locked nucleic acids (all-LNAs) correct alternative splicing abnormalities in myotonic dystrophy
por: Wojtkowiak-Szlachcic, Agnieszka, et al.
Publicado: (2015)

Ribonuclease H1-dependent hepatotoxicity caused by locked nucleic acid-modified gapmer antisense oligonucleotides
por: Kasuya, Takeshi, et al.
Publicado: (2016)

Alpha-l-Locked Nucleic Acid-Modified Antisense Oligonucleotides Induce Efficient Splice Modulation In Vitro
por: Raguraman, Prithi, et al.
Publicado: (2020)

Loop-armed DNA tetrahedron nanoparticles for delivering antisense oligos into bacteria
por: Hu, Yue, et al.
Publicado: (2020)

Down-modulation of cancer targets using locked nucleic acid (LNA)-based antisense oligonucleotides without transfection
por: Zhang, Y, et al.
Publicado: (2011)

A Locked Nucleic Acid Antisense Oligonucleotide (LNA) Silences PCSK9 and Enhances LDLR Expression In Vitro and In Vivo
por: Gupta, Nidhi, et al.
Publicado: (2010)

In vitro inhibition of porcine reproductive and respiratory syndrome virus replication by short antisense oligonucleotides with locked nucleic acid modification
por: Zhu, Lingyun, et al.
Publicado: (2018)

The intratracheal administration of locked nucleic acid containing antisense oligonucleotides induced gene silencing and an immune-stimulatory effect in the murine lung
por: Uemura, Yasunori, et al.
Publicado: (2017)

Rational Design of Short Locked Nucleic Acid-Modified 2′-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro
por: Le, Bao T., et al.
Publicado: (2017)

Reversal of phenotypes in MECP2 duplication mice using genetic rescue or antisense oligos
por: Sztainberg, Yehezkel, et al.
Publicado: (2015)

Immunotherapy in pancreatic cancer: Unleash its potential through novel combinations
por: Guo, Songchuan, et al.
Publicado: (2017)

Intramuscular Evaluation of Chimeric Locked Nucleic Acid/2′OMethyl-Modified Antisense Oligonucleotides for Targeted Exon 23 Skipping in Mdx Mice
por: Georgiadou, Michaella, et al.
Publicado: (2021)

Tolerability and safety of GS-101 eye drops, an antisense oligonucleotide to insulin receptor substrate-1: a ‘first in man’ Phase I investigation
por: Kain, Hermann, et al.
Publicado: (2009)

Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates
por: Straarup, Ellen Marie, et al.
Publicado: (2010)

Prospects for Antisense Nucleic Acid Therapy of Cancer and AIDS
por: Tidd, D.M.
Publicado: (1993)

A Phase I Study of the Combination of Pexidartinib and Sirolimus to Target Tumor-Associated Macrophages in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors
por: Manji, Gulam A., et al.
Publicado: (2021)

Locked and Unlocked Nucleosides in Functional Nucleic Acids
por: Doessing, Holger, et al.
Publicado: (2011)

Randomised clinical trial: a phase 1b study of GB004, an oral HIF‐1α stabiliser, for treatment of ulcerative colitis
por: Danese, Silvio, et al.
Publicado: (2022)

RNA Interference-Guided Targeting of Hepatitis C Virus Replication with Antisense Locked Nucleic Acid-Based Oligonucleotides Containing 8-oxo-dG Modifications
por: Mutso, Margit, et al.
Publicado: (2015)

Extracellular vesicles mediated exocytosis of antisense peptide nucleic acids
por: Malik, Shipra, et al.
Publicado: (2021)

The crystal structure of an ‘All Locked’ nucleic acid duplex
por: Eichert, André, et al.
Publicado: (2010)

The free energy of locking a ring: Changing a deoxyribonucleoside to a locked nucleic acid
por: Xu, You, et al.
Publicado: (2017)

LncRNA PVT1 Is a Poor Prognosticator and Can Be Targeted by PVT1 Antisense Oligos in Gastric Adenocarcinoma
por: Li, Yuan, et al.
Publicado: (2020)

Randomised clinical trial: 2% taurolidine versus 0.9% saline locking in patients on home parenteral nutrition
por: Wouters, Y., et al.
Publicado: (2018)

Molecular dynamics simulations of acyclic analogs of nucleic acids for antisense inhibition
por: Galindo-Murillo, Rodrigo, et al.
Publicado: (2020)

Stability and Mismatch Discrimination of Locked Nucleic Acid–DNA Duplexes
por: Owczarzy, Richard, et al.
Publicado: (2011)

Locked nucleic acid oligomers as handles for single molecule manipulation
por: Berezney, John P., et al.
Publicado: (2014)

A New Antisense Phosphoryl Guanidine Oligo-2′-O-Methylribonucleotide Penetrates Into Intracellular Mycobacteria and Suppresses Target Gene Expression
por: Skvortsova, Yulia V., et al.
Publicado: (2019)

Impact of analysis of the sentinel lymph node by one-step nucleic acid amplification (OSNA) compared to conventional histopathology on axillary and systemic treatment: data from the Dutch nationwide cohort of breast cancer patients
por: van Haaren, Elisabeth R. M., et al.
Publicado: (2023)

Targeting chromosomal sites with locked nucleic acid-modified triplex-forming oligonucleotides: study of efficiency dependence on DNA nuclear environment
por: Brunet, Erika, et al.
Publicado: (2006)

Nucleic acid binding proteins affect the subcellular distribution of phosphorothioate antisense oligonucleotides
por: Bailey, Jeffrey K., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_uej8uceo2mmjqptgfofvo4734c